{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:43:46Z","timestamp":1787499826714,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006390","name":"Universit\u00e9 de Lausanne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medical Genetics"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ejmg.2019.103703","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T13:52:49Z","timestamp":1560261169000},"page":"103703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Fabry disease caused by the GLA p.Phe113Leu (p.F113L) variant: Natural history in males"],"prefix":"10.1016","volume":"63","author":[{"given":"Jo\u00e3o P.","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albina","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Barbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcia","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 P.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Teixeira-e-Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odete","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e1tia","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Teresa","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia E.","family":"Jurca-Simina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique P.","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmg.2019.103703_bib1","first-page":"28","article-title":"Miocardiopatia hipertr\u00f3fica secund\u00e1ria a Doen\u00e7a de Fabry: evid\u00eancia de um efeito de fundador na regi\u00e3o de Guimar\u00e3es","volume":"32","author":"Azevedo","year":"2013","journal-title":"Rev. Port. Cardiol."},{"issue":"4","key":"10.1016\/j.ejmg.2019.103703_bib2","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.ejmg.2019.103703_bib3","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltim.)"},{"issue":"6","key":"10.1016\/j.ejmg.2019.103703_bib4","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/humu.22981","article-title":"HGVS recommendations for the description of sequence variants: 2016 update","volume":"37","author":"den Dunnen","year":"2016","journal-title":"Hum. Mutat."},{"issue":"4","key":"10.1016\/j.ejmg.2019.103703_bib5","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.ejmg.2019.103703_bib6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"issue":"39","key":"10.1016\/j.ejmg.2019.103703_bib7","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task Force for the diagnosis and management of hypertrophic cardiomyopathy of the european society of cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.ejmg.2019.103703_bib8","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF03401671","article-title":"Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes","volume":"3","author":"Eng","year":"1997","journal-title":"Mol. Med(Cam. Mass)"},{"issue":"19","key":"10.1016\/j.ejmg.2019.103703_bib9","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1111\/j.1742-4658.2007.06041.x","article-title":"Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors","volume":"274","author":"Fan","year":"2007","journal-title":"FEBS J."},{"issue":"2","key":"10.1016\/j.ejmg.2019.103703_bib10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ymgme.2014.11.004","article-title":"The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies","volume":"114","author":"Ferreira","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ejmg.2019.103703_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJM200107053450104","article-title":"Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy","volume":"345","author":"Frustaci","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmg.2019.103703_bib12","series-title":"Fabry Disease","first-page":"3","article-title":"Molecular genetics of fabry disease and genotype\u2013phenotype correlation","author":"Gal","year":"2010"},{"key":"10.1016\/j.ejmg.2019.103703_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2350-11-19","article-title":"Frequency of Fabry disease in male and female haemodialysis patients in Spain","volume":"11","author":"Gaspar","year":"2010","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.ejmg.2019.103703_bib14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.ejmg.2019.103703_bib15","first-page":"S111","article-title":"Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies","volume":"47","author":"Germain","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.ejmg.2019.103703_bib16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejmg.2019.103703_bib17","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/mgg3.389","article-title":"Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: a multicenter Fabry Registry study","volume":"6","author":"Germain","year":"2018","journal-title":"Mol.Genet. Genomic. Med."},{"issue":"11","key":"10.1016\/j.ejmg.2019.103703_bib18","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1503\/cmaj.1040847","article-title":"Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies","volume":"172","author":"Goldenberg","year":"2005","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"issue":"1","key":"10.1016\/j.ejmg.2019.103703_bib19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2337\/diacare.28.1.164","article-title":"Diabetic nephropathy: diagnosis, prevention, and treatment","volume":"28","author":"Gross","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejmg.2019.103703_bib20","series-title":"Fabry Disease","first-page":"21","article-title":"The structure of human \u03b1-galactosidase a and implications for fabry disease","author":"Guce","year":"2010"},{"issue":"2","key":"10.1016\/j.ejmg.2019.103703_bib21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/hrt.2010.200188","article-title":"Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study","volume":"97","author":"Hag\u00e8ge","year":"2011","journal-title":"Heart"},{"issue":"19","key":"10.1016\/j.ejmg.2019.103703_bib22","article-title":"Epub ahead of print]. Fabry disease in cardiology practice: literature review and expert point of view","volume":"27","author":"Hag\u00e8ge","year":"2019","journal-title":"Arch Cardiovasc Dis Feb"},{"key":"10.1016\/j.ejmg.2019.103703_bib23","series-title":"A Primer of Population Genetics","author":"Hartl","year":"2000"},{"issue":"2","key":"10.1016\/j.ejmg.2019.103703_bib24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5414\/CN108053","article-title":"Prevalence of Fabry's disease within hemodialysis patients in Spain","volume":"81","author":"Herrera","year":"2014","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.ejmg.2019.103703_bib25","series-title":"Human Gene Mutation Database","author":"HGMD\u00ae","year":"2019"},{"issue":"8","key":"10.1016\/j.ejmg.2019.103703_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.006309","article-title":"Discrepant measurements of maximal left ventricular wall thickness between cardiac magnetic resonance imaging and echocardiography in patients with hypertrophic cardiomyopathy","volume":"10","author":"Hindieh","year":"2017","journal-title":"Circ. Cardiovasc. Imaging."},{"issue":"2","key":"10.1016\/j.ejmg.2019.103703_bib27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/BJ20070479","article-title":"Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin","volume":"406","author":"Ishii","year":"2007","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmg.2019.103703_bib28","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney Int. Suppl."},{"issue":"1","key":"10.1016\/j.ejmg.2019.103703_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJM199601043340103","article-title":"Blood pressure and end-stage renal disease in men","volume":"334","author":"Klag","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ejmg.2019.103703_bib30","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"Lang","year":"2005","journal-title":"J. Am. Soc. Echocardiogr."},{"issue":"4","key":"10.1016\/j.ejmg.2019.103703_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193550","article-title":"Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation","volume":"13","author":"Lavalle","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ejmg.2019.103703_bib32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann. Intern. Med."},{"issue":"10","key":"10.1016\/j.ejmg.2019.103703_bib33","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1093\/ndt\/14.10.2271","article-title":"Hypertensive nephrosclerosis: pathogenesis and prevalence. Essential hypertension is an important cause of end-stage renal disease","volume":"14","author":"Luke","year":"1999","journal-title":"Nephrol. Dial. Transplant."},{"issue":"4","key":"10.1016\/j.ejmg.2019.103703_bib34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00439-005-1300-5","article-title":"Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes","volume":"117","author":"Matsuzawa","year":"2005","journal-title":"Hum. Genet."},{"issue":"2","key":"10.1016\/j.ejmg.2019.103703_bib35","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2215\/CJN.05570809","article-title":"Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy","volume":"5","author":"Mignani","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"25","key":"10.1016\/j.ejmg.2019.103703_bib36","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2007.06.062","article-title":"Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy","volume":"50","author":"Monserrat","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"17","key":"10.1016\/j.ejmg.2019.103703_bib37","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/eurheartj\/ehv013","article-title":"Current but not past smoking increases the risk of cardiac events: insights from coronary computed tomographic angiography","volume":"36","author":"Nakanishi","year":"2015","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.ejmg.2019.103703_bib38","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmg.2019.103703_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/TACG.S146022","article-title":"Multiple phenotypic domains of Fabry disease and their relevance for establishing genotype\u2013phenotype correlations","volume":"12","author":"Oliveira","year":"2019","journal-title":"Appl. Clin. Genet."},{"issue":"Suppl. 2","key":"10.1016\/j.ejmg.2019.103703_bib40","doi-asserted-by":"crossref","first-page":"S405","DOI":"10.1007\/s10545-008-0972-0","article-title":"The g.1170C>T polymorphism of the 5' untranslated region of the human alpha-galactosidase gene is associated with decreased enzyme expression--evidence from a family study","volume":"31","author":"Oliveira","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ejmg.2019.103703_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3858\/emm.2009.41.1.001","article-title":"Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in Korean patients with Fabry disease","volume":"41","author":"Park","year":"2009","journal-title":"Exp. Mol. Med."},{"issue":"13","key":"10.1016\/j.ejmg.2019.103703_bib42","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur. Heart J."},{"issue":"27","key":"10.1016\/j.ejmg.2019.103703_bib43","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.ejmg.2019.103703_bib44","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ejmg.2019.103703_bib45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","article-title":"Fabry disease","volume":"122","author":"Schiffmann","year":"2009","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.ejmg.2019.103703_bib46","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1034\/j.1399-0004.2003.630107.x","article-title":"Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients","volume":"63","author":"Senechal","year":"2003","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ejmg.2019.103703_bib47","article-title":"Fabry disease in Portugal: insights from the male patients","volume":"25","author":"Soares","year":"2016","journal-title":"Nascer e Crescer"},{"issue":"1","key":"10.1016\/j.ejmg.2019.103703_bib48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"issue":"194","key":"10.1016\/j.ejmg.2019.103703_bib49","first-page":"115","article-title":"A diferen\u00e7a de esperan\u00e7a de vida entre homens e mulheres: Portugal de 1940 a 2007","volume":"XLV","author":"Tiago-de-Oliveira","year":"2010","journal-title":"An\u00e1lise Soc."},{"issue":"33","key":"10.1016\/j.ejmg.2019.103703_bib50","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.2174\/13816128113199990352","article-title":"Anderson-Fabry disease: a multiorgan disease","volume":"19","author":"Tuttolomondo","year":"2013","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmg.2019.103703_bib51","series-title":"2015 \u2013 2020 Dietary Guidelines for Americans","year":"2015"},{"issue":"2","key":"10.1016\/j.ejmg.2019.103703_bib52","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ymgme.2014.08.007","article-title":"Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis","volume":"114","author":"van der Tol","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ejmg.2019.103703_bib53","series-title":"Fabry Disease","first-page":"211","article-title":"Renal manifestations of fabry disease","author":"Warnock","year":"2010"},{"key":"10.1016\/j.ejmg.2019.103703_bib54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1750-1172-8-116","article-title":"Fibrosis: a key feature of Fabry disease with potential therapeutic implications","volume":"8","author":"Weidemann","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ejmg.2019.103703_bib55","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol. Genet. Metab."}],"container-title":["European Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769721219301983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769721219301983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:47:53Z","timestamp":1761709673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769721219301983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1769721219301983"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmg.2019.103703","relation":{},"ISSN":["1769-7212"],"issn-type":[{"value":"1769-7212","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fabry disease caused by the GLA p.Phe113Leu (p.F113L) variant: Natural history in males","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medical Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmg.2019.103703","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103703"}}